Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Cognoa
AddedFeb 15, 2024
UpdatedJun 18, 2026
Cognoa

Cognoa

Series B

Cognoa, Inc.: Global provider of digital diagnostic and therapeutic healthcare solutions for children and families.

HQ
Palo Alto, CA, US
Founded
2013
Overview
Compare
Fundraising
Employees
Website

Cognoa is a healthcare technology company focused on developing digital diagnostic and therapeutic solutions for children and families. Their mission centers on enabling early interventions for developmental conditions, particularly autism, through innovative software products. The company's flagship product, Canvas Dx, is the first FDA-authorized digital diagnostic aid for autism, designed to facilitate rapid and equitable diagnosis.

Cognoa's approach aims to address the critical issue of delayed diagnosis in developmental conditions, which often occurs years after the optimal intervention window. By leveraging digital technologies, Cognoa strives to optimize healthcare resources, save time in the diagnostic process, and ultimately improve outcomes for children and families worldwide. Their work represents a significant step forward in making early diagnosis and intervention more accessible and efficient.

Cognoa - Similar Companies

Neurotrack logo

Neurotrack

neurotrack.com

CognitiveCare logo

CognitiveCare

cognitivecare.com

SpectrumAi logo

SpectrumAi

spectrumai.com

Cogitativo logo

Cogitativo

cogitativo.com

SynapDx logo

SynapDx

Connected Mind logo

Connected Mind

CogniFit logo

CogniFit

cognifit.com

Cogniant.co logo

Cogniant.co

cogniant.co

CognitiveHealth Technologies logo

CognitiveHealth Technologies

Cognision logo

Cognision

Digital Diagnostics logo

Digital Diagnostics

EarliTec Diagnostics logo

EarliTec Diagnostics

earlitecdx.com

BrainCheck logo

BrainCheck

braincheck.com

Cognita Labs logo

Cognita Labs

cognitalabs.com

Passage Health logo

Passage Health

passagehealth.com

Cognoa - Quick Facts

Who are Cognoa's competitors?

Companies similar to Cognoa include Neurotrack, CognitiveCare, SpectrumAi and Cogitativo.

When was Cognoa founded?

Cognoa was founded in 2013.

Where is Cognoa's headquarters located?

Cognoa's headquarters is located in Palo Alto, CA, US.

When was Cognoa's last funding round?

Cognoa's most recent funding round was for $73.1M (USD) in November 2022.

How much has Cognoa raised to-date?

As of Nov 14, 2022, Cognoa has raised a total of $127M (USD).

How many employees does Cognoa have?

Cognoa has 77 employees as of Feb 4, 2024.

Cognoa - Classification

Ownership
  • Equity
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Consumers
  • Enterprise
Main Product
  • Digital Diagnostics
  • Therapeutics
Tags
  • Healthtech
  • SaaS
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7372Prepackaged Software
Show 10 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 620000Health Care and Social Assistance
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7371Computer Programming Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified